Becaplermin biosimilar - USV

Drug Profile

Becaplermin biosimilar - USV

Alternative Names: PDGF-BB - USV; Platelet-derived growth factor B-chain homodimer - USV

Latest Information Update: 22 May 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator USV
  • Class Blood proteins; Cicatrizants; Growth factors; Recombinant proteins
  • Mechanism of Action Platelet-derived growth factor receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Diabetic foot ulcer

Most Recent Events

  • 22 May 2015 USV files a patent for becaplermin gel formulation in India (USV product pipeline, May 2015)
  • 22 May 2015 Preclinical trials in Diabetic foot ulcer in India (Topical) (USV product pipeline, May 2015)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top